PDF(Pubmed)
Abstract：
Diabetic foot ulcer (DFU) is a severe complication of diabetes, preceding most diabetes-related amputations. DFUs require over US$9 billion for yearly treatment and are now a global public health issue. DFU occurs in the setting of ischemia, infection, neuropathy, and metabolic disorders that result in poor wound healing and poor treatment options. Recently, stem cell therapy has emerged as a new interventional strategy to treat DFU and appears to be safe and effective in both preclinical and clinical trials. However, variability in the stem cell type and origin, route and protocol for administration, and concomitant use of angioplasty confound easy interpretation and generalization of the results.
The PubMed, Google Scholar, and EMBASE databases were searched and 89 preclinical and clinical studies were selected for analysis.
There was divergence between preclinical and clinical studies regarding stem cell type, origin, and delivery techniques. There was heterogeneous preclinical and clinical study design and few randomized clinical trials. Granulocyte-colony stimulating factor was employed in some studies but with differing protocols. Concomitant performance of angioplasty with stem cell therapy showed increased efficiency compared to either therapy alone.
Stem cell therapy is an effective treatment for diabetic foot ulcers and is currently used as an alternative to amputation for some patients without other options for revascularization. Concordance between preclinical and clinical studies may help design future randomized clinical trials.
The PubMed, Google Scholar, and EMBASE databases were searched and 89 preclinical and clinical studies were selected for analysis.
There was divergence between preclinical and clinical studies regarding stem cell type, origin, and delivery techniques. There was heterogeneous preclinical and clinical study design and few randomized clinical trials. Granulocyte-colony stimulating factor was employed in some studies but with differing protocols. Concomitant performance of angioplasty with stem cell therapy showed increased efficiency compared to either therapy alone.
Stem cell therapy is an effective treatment for diabetic foot ulcers and is currently used as an alternative to amputation for some patients without other options for revascularization. Concordance between preclinical and clinical studies may help design future randomized clinical trials.
摘要：
糖尿病足溃疡（DFU）是糖尿病的严重并发症，在大多数与糖尿病相关的截肢手术之前。DFU每年需要超过90亿美元的治疗，现在已成为全球公共卫生问题。DFU发生在缺血的背景下，感染,神经病,和代谢紊乱导致不良的伤口愈合和不良的治疗选择。最近,干细胞疗法已成为治疗DFU的一种新的介入策略，在临床前和临床试验中似乎都是安全有效的。然而,干细胞类型和来源的变异性，给药途径和方案，血管成形术的同时使用使结果易于解释和概括。
PubMed,谷歌学者，我们检索了EMBASE数据库,选择了89项临床前和临床研究进行分析.
关于干细胞类型的临床前和临床研究之间存在差异，origin,和交付技术。临床前和临床研究设计不均匀，随机临床试验很少。在一些研究中采用了粒细胞集落刺激因子，但方案不同。与任何单独的治疗相比，血管成形术与干细胞治疗的伴随表现显示出增加的效率。
干细胞疗法是糖尿病足溃疡的有效治疗方法，目前被用作一些没有其他血运重建选择的患者的截肢替代方法。临床前和临床研究之间的一致性可能有助于设计未来的随机临床试验。
PubMed,谷歌学者，我们检索了EMBASE数据库,选择了89项临床前和临床研究进行分析.
关于干细胞类型的临床前和临床研究之间存在差异，origin,和交付技术。临床前和临床研究设计不均匀，随机临床试验很少。在一些研究中采用了粒细胞集落刺激因子，但方案不同。与任何单独的治疗相比，血管成形术与干细胞治疗的伴随表现显示出增加的效率。
干细胞疗法是糖尿病足溃疡的有效治疗方法，目前被用作一些没有其他血运重建选择的患者的截肢替代方法。临床前和临床研究之间的一致性可能有助于设计未来的随机临床试验。
